Edwards Lifesciences Corp SEC Filings

Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences (EW), reported a sale of 262 shares of common stock on 09/13/2025 at a price of $77.57 per share. After the reported transaction, the filing shows beneficial ownership of 7,926.9331 shares. The form notes this filing reflects changes in beneficial ownership only and includes a quarterly acquisition under the issuer's Employee Stock Purchase Plan.

Daveen Chopra, an officer (CVP, TMTT & Surgical) of Edwards Lifesciences Corporation (EW), received 3,205 restricted stock units (RSUs) on 09/11/2025 under the companys Long-Term Stock Incentive Compensation Program at an effective price of $0.0000. The RSUs are scheduled to vest in four equal annual installments beginning one year after the grant date. After this reported grant, the filing shows 34,201 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact and filed on 09/15/2025. The form notes it reflects changes in beneficial ownership only.

Edwards Lifesciences director and officer Wayne Markowitz reported two transactions in September 2025 affecting his holdings in Edwards Lifesciences (EW). On 09/11/2025 he was granted 6,410 restricted stock units (RSUs) under the companys Long-Term Stock Incentive Compensation Program; those RSUs vest in four equal annual installments beginning one year after the grant date. On 09/14/2025 he sold 650 shares of common stock at a price of $77.57 per share. After these transactions he beneficially owns 18,145.8708 shares directly. The Form 4 notes the RSU grant and also references quarterly ESPP share acquisitions; no derivative transactions were reported.

Edwards Lifesciences (EW) insider sale disclosed on Form 4. Reporting person Daveen Chopra, listed as an officer (CVP, TMTT), sold 2,500 shares of Edwards Lifesciences common stock on 08/25/2025 at a weighted average price of $81.946 per share. After the sale the filing reports 30,996 shares beneficially owned by the reporting person, held directly. The filing states the reported sale was executed in multiple trades at prices ranging from $81.9401 to $81.9500 and that the weighted average price is provided; the filer offers to supply detailed trade-by-trade information upon request. The form notes it reflects changes in beneficial ownership only and does not list other securities the reporting person may own.

Edwards Lifesciences (EW) Form 144 notifies of a proposed sale of 2,500 shares of common stock through Charles Schwab & Co., Inc. with an aggregate market value of $204,865.00. The sale is scheduled to occur approximately on 08/25/2025 on the NYSE. The shares being offered were acquired as equity compensation: 657 shares from RSU/PSU on 05/08/2022, 1,671 shares from a restricted stock lapse on 05/17/2022, and 172 shares from a restricted stock lapse on 05/03/2023. No securities were reported sold in the past three months on this form. The filer certifies compliance with the Rule 144 representation regarding material nonpublic information.

Edwards Lifesciences (EW) insider activity: On 08/18/2025, Larry L. Wood, Global President TAVR & Surg, reported option exercise and related open-market sales under a Rule 10b5-1 plan. He acquired 8,950 shares via exercise of employee stock options at an exercise price of $59.2567 and then sold 8,950 shares in multiple trades at a weighted average sale price of $78.0647.

Following these transactions, the filing shows Mr. Wood beneficially owns 215,850.3913 shares after the acquisition and 206,900.3913 after the sale; an additional 148.1703 shares are held indirectly in a 401(k). The 10b5-1 plan was adopted on February 27, 2025, and the report is signed by an attorney-in-fact on 08/18/2025.

Edwards Lifesciences (EW) Form 144 notice: An insider proposes a routine sale of 8,950 common shares through Charles Schwab & Co., with an aggregate market value of $698,679.00. The shares were acquired on 08/18/2025 via an employee stock option exercise and the planned sale date is listed as 08/18/2025. The filer previously sold 8,950 shares on 06/16/2025 for gross proceeds of $673,268.00. Outstanding shares are listed as 587,100,000, making this transaction immaterial relative to total shares outstanding.

Wellington Management reports beneficial ownership of 19,826,483 shares of Edwards Lifesciences common stock, equal to 3.38% of the class. The filing shows shared voting power of 18,601,111 shares and shared dispositive power of 19,826,483 shares, while sole voting and dispositive power are reported as zero. The securities are owned of record by clients of Wellington investment advisers.

The filing names the reporting entities (Wellington Management Group LLP; Wellington Group Holdings LLP; Wellington Investment Advisors Holdings LLP) and lists the Wellington investment advisers that control the client accounts. It also includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.